Baader Bank Aktiengesellschaft’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,888	Closed	-$3.71K	–	514
2026 Q1	$3.71K	Buy	+22,888	New	+$9.11K	﹤0.01%	413
2025 Q4	–	Sell	-20,739	Closed	-$8.63K	–	589
2025 Q3	$8.63K	Buy	20,739 +2,821	+16%	+$1.52K	﹤0.01%	474
2025 Q2	$5.99K	Buy	+17,918	New	+$10.6K	﹤0.01%	427

Other funds holding SGMO

AIM

Axiom Investment Management New York $150M AUM

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Baader Bank Aktiengesellschaft's SGMO Position: Q2 2026 in Review

Baader Bank Aktiengesellschaft sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 22,888 shares — an estimated $3.71K sold.

Baader Bank Aktiengesellschaft first reported a position in SGMO in Q2 2025 and held it in 3 quarters. The position peaked at $8.63K in Q3 2025. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Baader Bank Aktiengesellschaft reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 22,888 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $3.71K.
Baader Bank Aktiengesellschaft first reported a position in SANGAMO THERAPEUTICS INC in Q2 2025 and held it in 3 quarters.
Baader Bank Aktiengesellschaft's SANGAMO THERAPEUTICS INC position peaked at $8.63K in Q3 2025.
2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2026, filed 23 Jul 2026.